Nieves Martinez Lago MD PhD· @DraMartinezLago · X·· 19 小时前评分70
正文 · 原文
#ESMO26 🧬 Temab-A + BEV | Phase I
👥 83 pts | Refractory mCRC (3L+)
💊 c-MET ADC + BEV vs FTD/TPI + BEV
📊 Temab-A 2.4 mg/kg vs SOC:
🎯 ORR: 30% vs 0%
📈 mPFS: 6.8 vs 4.2 mo (HR 0.48)
⏳ mOS: 14.7 vs 10.2 mo (HR 0.62)
⚠️ G≥3 neutropenia: 33%
🚀 Promising activity! Phase III ongoing.
@OncoAlert
70 浏览 · 1 赞 · 1 转发 · 0 回复
会议摘要
1017P按 Developmental therapeutics 对上
Phase 1 first-in-human (FIH) results of YL211, a c-Met targeting antibody-drug conjugate (ADC), in patients (pts) with advanced solid tumors
https://esmocongress.esmo.orgNCT06110663NCT06110663按 - **标题 / Title：** A Study of HS-10241 Combined With Almonertinib Versus Platinum-based Chemotherapy in Treatment of Advanced NSCLC With MET Amplification After Failure of EGFR-TKI Therapy 对上
- **标题 / Title：** A Study of HS-10241 Combined With Almonertinib Versus Platinum-based Chemotherapy in Treatment of Advanced NSCLC With MET Amplification After Failure of EGFR-TKI Therapy
https://esmocongress.esmo.org来源：Nieves Martinez Lago MD PhD · x.com